Our Science

Overview

Hyper-selective targeting of inflammation to create better treatment options for patients

Inflammation is the body’s way of protecting itself against infection and injury. When activated appropriately by the immune system, acute inflammation can be life-saving response; when activated chronically, it can become very harmful, causing many serious diseases, including cardiovascular disease, cancer, rheumatological diseases, and metabolic disease. Available drugs and biologics, called immunomodulators, can reduce inflammation by modulating various immune system pathways, however, these treatments can interfere with normal immune system function. This leaves patients susceptible to serious side effects, such as fatal infections and cancers.

Abcentra has invented a way to target inflammatory responses specifically from oxidized lipoproteins. Targeting inflammation in this highly selective manner creates the possibility of reducing chronic inflammation without interfering with normal immune system functions, like fighting infection and cancer. By intervening at the intersection of accumulated damage from oxidative stress to lipoproteins and immune system activation, Abcentra aims to offer new and compelling treatments for a variety of inflammatory diseases.

Targeting Oxidized Lipoproteins

Abcentra is developing antibodies that target oxidized lipoproteins, such as oxidized low-density lipoprotein (oxLDL) and lipoprotein(a), or “Lp(a)” for short.

OxLDL is potent inflammatory mediator, implicated in serious inflammatory disease such as cardiovascular disease, psoriasis, rheumatoid arthritis, and cancer.

Lp(a) is a genetically determined, casual risk factor for premature heart disease, stroke, and aortic valve disease.

Orticumab

Our clinical-stage lead candidate, Orticumab, is being developed to treat inflammatory diseases. It is the first fully human antibody that targets a specific epitope on oxidized apolipoproteinB-100 (ox-apoB-100), which is the protein component of oxLDL.

Orticumab has strong scientific support and has been featured in several peer-reviewed publications.

Orticumab targeting oxLDL

Mechanism of Action

Orticumab works by targeted inhibition of inflammatory signaling from oxLDL.

orticumab localizes to oxLDL-rich inflammed tissue
orticumab forms an immune complex through binding densely-aggregated oxLDL
FcyR crosslinking an inhibitory signaling deactivates inflammatory activity in macrophages
Li et al (2013) Molecular Metabolism

Pipeline

Abcentra is developing a pipeline of antibodies that target oxidized lipoproteins for serious inflammatory diseases. See our pipeline for more information.